YO
Highly rated in
29
conditions
Highly rated in
29
conditions
Check Dr. Yasuhiro Oki's experience treating your condition:
About Dr. Yasuhiro Oki

Yasuhiro Oki is a Hematologist Oncology specialist and a Hematologist in San Ramon, California. Oki has been practicing medicine for over 25 years and is highly rated in 29 conditions, according to our data. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Texas.

His clinical research consists of co-authoring 151 peer reviewed articles and participating in 10 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Yasuhiro Oki it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
5601 Norris Canyon Rd, Suite 300, San Ramon, CA 94583
Background & Education
Graduate Institution
Other, 1998
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Eden Medical Center
Stanford Health Care - ValleyCare Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
Phase II Study of MK-2206 in Patients With Relapsed Lymphoma
A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma
Phase I/II of Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
View 9 Less Clinical Trials -

151 Total Publications

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors